Market open
Phathom Pharmaceuticals/$PHAT
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Phathom Pharmaceuticals
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Ticker
$PHAT
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
452
Website
PHAT Metrics
BasicAdvanced
$490M
-
-$5.68
0.72
-
Price and volume
Market cap
$490M
Beta
0.72
52-week high
$18.68
52-week low
$6.07
Average daily volume
1M
Financial strength
Current ratio
5.726
Quick ratio
5.449
Long term debt to equity
-266.214
Total debt to equity
-277.37
Interest coverage (TTM)
-4.33%
Management effectiveness
Return on assets (TTM)
-57.67%
Return on equity (TTM)
331.35%
Valuation
Price to revenue (TTM)
16.307
Price to book
-2.62
Price to tangible book (TTM)
-2.62
Price to free cash flow (TTM)
-1.729
Growth
Earnings per share change (TTM)
51.71%
3-year earnings per share growth (CAGR)
8.21%
What the Analysts think about PHAT
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Phathom Pharmaceuticals stock.
PHAT Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
PHAT Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
PHAT News
AllArticlesVideos
Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets
GlobeNewsWire·1 month ago
Phathom Pharmaceuticals, Inc. (PHAT) Q3 2024 Earnings Call Transcript
Seeking Alpha·2 months ago
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Phathom Pharmaceuticals stock?
Phathom Pharmaceuticals (PHAT) has a market cap of $490M as of January 24, 2025.
What is the P/E ratio for Phathom Pharmaceuticals stock?
The price to earnings (P/E) ratio for Phathom Pharmaceuticals (PHAT) stock is 0 as of January 24, 2025.
Does Phathom Pharmaceuticals stock pay dividends?
No, Phathom Pharmaceuticals (PHAT) stock does not pay dividends to its shareholders as of January 24, 2025.
When is the next Phathom Pharmaceuticals dividend payment date?
Phathom Pharmaceuticals (PHAT) stock does not pay dividends to its shareholders.
What is the beta indicator for Phathom Pharmaceuticals?
Phathom Pharmaceuticals (PHAT) has a beta rating of 0.72. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.